Vicarious Surgical News

Press Release: Vicarious Surgical to Report Fourth Quarter and Fiscal Year 2024 Financial Results on March 17, 2025

Dow JonesMar 3 16:06 ET

Morgan Stanley Fund: Humanoid robots will gradually enter the mass production phase by 2025.

Currently, the humanoid robot industry both domestically and internationally is mainly divided into three major forces: automotive companies, robot companies, and Internet companies. The primary demand for humanoid robots such as those from Tesla is the ability for scaled production and cost reduction.

Zhitong FinanceMar 3 06:55 ET

Goldman Sachs' research throws cold water on the situation: the turning point for humanoid robot technology remains unclear, and meaningful applications will take at least another five years!

Goldman Sachs believes that the humanoid robot H1 has only 19 degrees of freedom, making it still unable to handle complex and detailed tasks. At least in the next 2-3 years, it will be difficult for humanoid robots to achieve the same work efficiency as human workers. Meaningful applications are not expected for another 5-10 years.

wallstreetcnFeb 27 07:49 ET

Top Executives Make Strategic Moves With Vicarious Surgical Stock!

TipRanksFeb 21 21:07 ET

Insider Sale: CEO of $RBOT Sells 943 Shares

Quiver QuantitativeFeb 21 13:30 ET

Goldman Sachs Siasun Robot&Automation deep research (3): Humanoid robots may be nearing mass production, with turning points emerging in three areas.

Humanoid robots are rapidly developing, but overall technology has not yet met the requirements for large-scale application in the industrial or Consumer sectors. Goldman Sachs believes that the turning point for humanoid robot technology may occur in three areas: solving multiple general tasks, high success rates and sustained robustness, and rapid reasoning. Currently, the development of humanoid robots still faces some obstacles, such as the lack of original data needed for training.

wallstreetcnFeb 20 22:32 ET

Vicarious Surgical: Mazzola Will Be COO Until Effective Date, Responsibilities to Be Transitioned to Randy Clark, Co Pres >RBOT

Dow JonesFeb 18 16:11 ET

Vicarious Surgical Announces Planned Retirement of Chief Operating Officer

BusinesswireFeb 18 16:05 ET

Interest in AI-Powered MedTech is on the Rise: Key Stocks to Watch

Analysts NotebookFeb 13 06:50 ET

Home Healthcare Inflation Is Stubbornly High -- WSJ

WSJFeb 12 12:30 ET

China leads the body, NVIDIA aims to be the brain, and Tesla "integrates" — Morgan Stanley elaborates on the top 100 humanoid robot companies!

Morgan Stanley systematically sorted out 100 core listed companies in the Global humanoid robot Industry Chain from the three core links of "brain", "body" and "integrator" for the first time, and pointed out that China holds a 63% share in the humanoid robot supply chain, dominating the market, especially with significant advantages in the "body" segment, while technology giants like Tesla and NVIDIA have become key forces in each segment.

wallstreetcnFeb 6 22:41 ET

U.S. stock market movement | Robot Concept stocks rise, Palladyne AI (PDYN.US) increases by over 28%.

U.S. stocks in the Robot Concept sector surged strongly, and as of this report, Palladyne AI has increased by over 28%.

Zhitong FinanceJan 22 09:46 ET

Vicarious Surgical Secures Advisory Role With Former CFO

TipRanksJan 21 17:02 ET

BTIG Sticks to Its Hold Rating for Vicarious Surgical (RBOT)

TipRanksDec 7, 2024 10:36 ET · Ratings

Vicarious Surgical: Kelly Will Assist Co to Ensure Successful Transition Prior to His Departure, Which Is Slated for Jan 2 >RBOT

Dow JonesDec 6, 2024 16:07 ET

Express News | Vicarious Surgical Inc - William Kelly to Depart as CFO on January 2, 2025

ReutersDec 6, 2024 16:05 ET

Vicarious Surgical Announces Departure Of Chief Financial Officer >RBOT

Dow JonesDec 6, 2024 16:05 ET

Express News | Vicarious Surgical Announces Departure of Chief Financial Officer

ReutersDec 6, 2024 16:05 ET

Here's Why Vicarious Surgical (NYSE:RBOT) Must Use Its Cash Wisely

Yahoo FinanceNov 21, 2024 09:53 ET

Vicarious Surgical Is Maintained at Neutral by Piper Sandler

Dow JonesNov 13, 2024 12:07 ET · Ratings